The passing of the COVID-relief package titled the ‘Consolidated Appropriations Act, 2021‘ (“CAA 2021”) extended the §45L Energy Efficient Home Credit (§45L Credit) through December 31, 2021 and made permanent the §179D Energy Efficient Commercial Building Deduction (§179D Deduction). These two valuable tax incentives encourage energy efficient design in both residential and commercial construction.
By now everyone has most likely seen that President Trump finally signed the second covid relief bill (Consolidated Appropriations Act or “CAA”) and passed it into law. While this is obviously good news for millions of Americans during this pandemic, this new law has HUGE implications to corporate 2020 R & D tax credit study.
There are many intriguing tax provisions which appear in year-end coronavirus relief bill, which was just passed by Congress and enacted into law with the President’s signature.
The state of New Jersey allows a qualified business enterprise to claim a state R&D tax credit for these qualified research expenses.
With all the drama and complexities of 2020, the closing months of the year are at least starting to show some light of clarity and new beginnings. From the announcement of potential lifesaving vaccines to, of all things, new announcements for the deductibility of Payroll Protection Plan funding, taxpayers now can sigh a little relief from a difficult year.
Massachusetts companies can now calculate their Massachusetts research credit using a new simplified method, opening up opportunities to companies that did not meet documentation requirements previously or were obligated to use the maximum amount of 16% per code section 830 CMR 63.38M.1(5)(a)1.
Some taxpayers may have a reduced 2019 R&D tax credit as the result of a negative impact of the Payroll Protection Plan loan program, an impact unintended by Congress.
On July 23, U.S. Rep. Jackie Walorski (R-IN) along with cosponsor Rep. Jodey Arrington (R-TX) sponsored H.R. 7766. This legislation would double the traditional research and development tax credits, and make it easier for small businesses and start ups to access the tax credit incentive.
Any company producing new antibiotics or infection fighting equipment, utilized to combat COVID-19 are certainly at the forefront of all medical research being conducted in the U.S. currently. These lifesaving efforts can be supported by the R&D tax credits.
Manufacturing companies are responding by pivoting their operations to produce products to help in the fight against COVID-19.
